lactic acid has been researched along with Metabolic Syndrome in 22 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Increased blood lactate or uric acid (UA) levels are associated with an increased risk of metabolic syndrome (MS)." | 9.30 | Interaction Between Lactate and Uric Acid is Associated With a Higher Prevalence of Metabolic Syndrome: A Community-Based Study. ( Li, F; Pan, H; Ren, M; Wu, M; Xu, M; Yan, D; Zhang, J, 2019) |
| "The purpose of the study was to determine the effect of native and selenium-modified mineral waters on metabolic syndrome models." | 8.12 | [EXPERIMENTAL JUSTIFICATION OF CORRECTIVE ACTION OF NATIVE AND SELENIUM-MODIFIED MINERAL WATERS ON METABOLIC SYNDROME MODEL]. ( Abramtsova, A; Akhkubekova, N; Chalaya, E; Efimenko, N; Uzdenov, M, 2022) |
| "Increased blood lactate or uric acid (UA) levels are associated with an increased risk of metabolic syndrome (MS)." | 5.30 | Interaction Between Lactate and Uric Acid is Associated With a Higher Prevalence of Metabolic Syndrome: A Community-Based Study. ( Li, F; Pan, H; Ren, M; Wu, M; Xu, M; Yan, D; Zhang, J, 2019) |
| "The purpose of the study was to determine the effect of native and selenium-modified mineral waters on metabolic syndrome models." | 4.12 | [EXPERIMENTAL JUSTIFICATION OF CORRECTIVE ACTION OF NATIVE AND SELENIUM-MODIFIED MINERAL WATERS ON METABOLIC SYNDROME MODEL]. ( Abramtsova, A; Akhkubekova, N; Chalaya, E; Efimenko, N; Uzdenov, M, 2022) |
| "Metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM) are associated with macro- and microcirculatory complications that reduce physical performance." | 2.82 | Effects of Wearing Compression Stockings on the Physical Performance of T2DM Men with MetS. ( Bloch, W; Brinkmann, C; Brixius, K; Grau, M; Hermann, R; Kerzel, H; Kohl-Bareis, M; Latsch, J; Reinhardt, L; Rühl, E, 2016) |
| "Metabolic syndrome is a leading medical concern that affects one billion people worldwide." | 1.72 | High-Molecular-Weight Dextran-Type Exopolysaccharide Produced by the Novel ( Abosalha, A; Ahmad, W; Anwar, MA; Ashfaq, I; Boyajian, JL; Hayat, A; Islam, P; Nasir, A; Prakash, S; Rehman, MU; Schaly, S; Thareja, R, 2022) |
| "Metabolic syndrome is an agglomeration of disorders including obesity, diabetes and cardiovascular diseases and characterized as chronic mild inflammation which elevates the circulatory inflammatory markers." | 1.51 | High fat diet administration leads to the mitochondrial dysfunction and selectively alters the expression of class 1 GLUT protein in mice. ( Jha, D; Mitra Mazumder, P, 2019) |
| "HR, power output (W), percent dehydration, intestinal and skin temperature (TINT and TSK), mean arterial pressure, cardiac output (CO), stroke volume (SV), and blood lactate concentration (La) were measured at the initial and latter stages of each trial to assess time-dependent drift." | 1.46 | Cardiovascular Drift during Training for Fitness in Patients with Metabolic Syndrome. ( Mora-Rodriguez, R; Morales-Palomo, F; Ortega, JF; Pallares, JG; Ramirez-Jimenez, M, 2017) |
| "Glucose tolerance and hyperinsulinemia improved (P < 0." | 1.43 | Isocaloric fructose restriction and metabolic improvement in children with obesity and metabolic syndrome. ( Erkin-Cakmak, A; Gugliucci, A; Lustig, RH; Mulligan, K; Noworolski, SM; Schwarz, JM; Tai, VW; Wen, MJ, 2016) |
| "In addition, intrauterine growth retardation (IUGR) increases the susceptibility of offspring to high-fat (HF) diet-induced metabolic syndrome." | 1.38 | Intrauterine growth retardation increases the susceptibility of pigs to high-fat diet-induced mitochondrial dysfunction in skeletal muscle. ( Chen, D; He, J; Huang, Z; Liu, J; Mao, X; Yao, Y; Yu, B; Zheng, P, 2012) |
| "Metabolic syndrome is a disease that today affects millions of people around the world." | 1.37 | Impact of early fructose intake on metabolic profile and aerobic capacity of rats. ( Botezelli, JD; Cambri, LT; Ghezzi, AC; Mello, MA; Ribeiro, C, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (13.64) | 29.6817 |
| 2010's | 13 (59.09) | 24.3611 |
| 2020's | 6 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Abramtsova, A | 1 |
| Uzdenov, M | 1 |
| Efimenko, N | 1 |
| Chalaya, E | 1 |
| Akhkubekova, N | 1 |
| Ahmad, W | 1 |
| Boyajian, JL | 1 |
| Abosalha, A | 1 |
| Nasir, A | 1 |
| Ashfaq, I | 1 |
| Islam, P | 1 |
| Schaly, S | 1 |
| Thareja, R | 1 |
| Hayat, A | 1 |
| Rehman, MU | 1 |
| Anwar, MA | 1 |
| Prakash, S | 1 |
| Hasan, EK | 1 |
| Mshimesh, BAR | 1 |
| Rzoqi, SS | 1 |
| Aziz, LSA | 1 |
| Khazaal, FAK | 1 |
| Marzooq, AA | 1 |
| Abudlqader, EH | 1 |
| Torres, G | 2 |
| Crowther, NJ | 2 |
| Rogers, G | 2 |
| Broskey, NT | 1 |
| Zou, K | 2 |
| Dohm, GL | 2 |
| Houmard, JA | 3 |
| DE-Cleva, R | 1 |
| Cardia, L | 1 |
| Vieira-Gadducci, A | 1 |
| Greve, JM | 1 |
| Santo, MA | 1 |
| Pan, H | 1 |
| Yan, D | 1 |
| Xu, M | 1 |
| Li, F | 1 |
| Ren, M | 1 |
| Zhang, J | 1 |
| Wu, M | 1 |
| Jha, D | 1 |
| Mitra Mazumder, P | 1 |
| Erkin-Cakmak, A | 2 |
| Bains, Y | 1 |
| Caccavello, R | 1 |
| Noworolski, SM | 2 |
| Schwarz, JM | 2 |
| Mulligan, K | 2 |
| Lustig, RH | 2 |
| Gugliucci, A | 2 |
| Jones, TE | 1 |
| Pories, WJ | 1 |
| Tanner, CJ | 2 |
| Zheng, D | 1 |
| Coen, PM | 1 |
| Goodpaster, BH | 1 |
| Kraus, WE | 2 |
| Grubišić, V | 1 |
| Parpura, V | 1 |
| Tai, VW | 1 |
| Wen, MJ | 1 |
| Brinkmann, C | 1 |
| Hermann, R | 1 |
| Rühl, E | 1 |
| Kerzel, H | 1 |
| Reinhardt, L | 1 |
| Grau, M | 1 |
| Latsch, J | 1 |
| Kohl-Bareis, M | 1 |
| Bloch, W | 1 |
| Brixius, K | 1 |
| Menni, C | 1 |
| Migaud, M | 1 |
| Glastonbury, CA | 1 |
| Beaumont, M | 1 |
| Nikolaou, A | 1 |
| Small, KS | 1 |
| Brosnan, MJ | 1 |
| Mohney, RP | 1 |
| Spector, TD | 1 |
| Valdes, AM | 1 |
| Vinod, M | 1 |
| Patankar, JV | 1 |
| Sachdev, V | 1 |
| Frank, S | 1 |
| Graier, WF | 1 |
| Kratky, D | 1 |
| Kostner, GM | 1 |
| Morales-Palomo, F | 1 |
| Ramirez-Jimenez, M | 1 |
| Ortega, JF | 1 |
| Pallares, JG | 1 |
| Mora-Rodriguez, R | 1 |
| Crawford, SO | 1 |
| Ambrose, MS | 1 |
| Hoogeveen, RC | 1 |
| Brancati, FL | 1 |
| Ballantyne, CM | 1 |
| Young, JH | 1 |
| Ghezzi, AC | 1 |
| Cambri, LT | 1 |
| Ribeiro, C | 1 |
| Botezelli, JD | 1 |
| Mello, MA | 1 |
| Liu, J | 1 |
| Chen, D | 1 |
| Yao, Y | 1 |
| Yu, B | 1 |
| Mao, X | 1 |
| He, J | 1 |
| Huang, Z | 1 |
| Zheng, P | 1 |
| Hittel, DS | 1 |
| Hoffman, EP | 1 |
| Mäkinen, VP | 1 |
| Soininen, P | 1 |
| Forsblom, C | 1 |
| Parkkonen, M | 1 |
| Ingman, P | 1 |
| Kaski, K | 1 |
| Groop, PH | 1 |
| Ala-Korpela, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Exercise Training as a Non-pharmacological Treatment for Metabolic Syndrome and Its Interactions With Subjects Habitual Medications.[NCT03019796] | Early Phase 1 | 40 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| [NCT00200993] | Phase 2 | 0 participants | Interventional | 1998-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Nude body weight. Value is the difference between the placebo and antihypertensive medication. (NCT03019796)
Timeframe: Subject tested before and after 4 months of training. At baseline tested with and without medication separated 72 hours. Post training tested with and without medication separated 72 hours.
| Intervention | kg (Mean) | |
|---|---|---|
| BEFORE TRAINING | AFTER TRAINING | |
| MEDICATED | 92.1 | 90.0 |
| PLACEBO | 92.5 | 90.8 |
Determined using a ECG-gated automated sphygmomanometer. Value is the difference between the placebo and antihypertensive medication. (NCT03019796)
Timeframe: Subject tested before and after 4 months of training. At baseline tested with and without medication separated 72 hours. Post training tested with and without medication separated 72 hours.
| Intervention | mmHg (Mean) | |
|---|---|---|
| BEFORE TRAINING | AFTER TRAINING | |
| MEDICATED | 75 | 72 |
| PLACEBO | 79 | 77 |
"Index of cardiorespiratory fitness assessed during an incremental cycle-ergometer test using an indirect calorimetry system.~Value is the difference between the placebo and antihypertensive medication." (NCT03019796)
Timeframe: Subject tested before and after 4 months of training. At baseline tested with and without medication separated 72 hours. Post training tested with and without medication separated 72 hours.
| Intervention | Liters of O2/kg weight/min (Mean) | |
|---|---|---|
| BEFORE TRAINING | AFTER TRAINING | |
| MEDICATED | 2.26 | 2.49 |
| PLACEBO | 2.26 | 2.49 |
"Calculated in grams per min during the incremental cycloergometer test wih the use of indirect calorimetry system.~Value is the difference between the placebo and antihypertensive medication." (NCT03019796)
Timeframe: Subject tested before and after 4 months of training. At baseline tested with and without medication separated 72 hours. Post training tested with and without medication separated 72 hours.
| Intervention | grams/min (Mean) | |
|---|---|---|
| BEFORE TRAINING | AFTER TRAINING | |
| MEDICATED | 0.24 | 0.28 |
| PLACEBO | 0.24 | 0.28 |
Determined using a ECG-gated automated sphygmomanometer. Value is the difference between the placebo and antihypertensive medication. (NCT03019796)
Timeframe: Subject tested before and after 4 months of training. At baseline tested with and without medication separated 72 hours. Post training tested with and without medication separated 72 hours.
| Intervention | mmHg (Mean) | |
|---|---|---|
| BEFORE TRAINING | AFTER TRAINING | |
| MEDICATED | 92 | 89 |
| PLACEBO | 97 | 96 |
Determined using a ECG-gated automated sphygmomanometer. Value is the difference between the placebo and antihypertensive medication. (NCT03019796)
Timeframe: Subject tested before and after 4 months of training. At baseline tested with and without medication separated 72 hours. Post training tested with and without medication separated 72 hours.
| Intervention | mmHg (Mean) | |
|---|---|---|
| BEFORE TRAINING | AFTER TRAINING | |
| MEDICATED | 126 | 124 |
| PLACEBO | 134 | 133 |
1 review available for lactic acid and Metabolic Syndrome
| Article | Year |
|---|---|
Plasma Lactate as a Marker for Metabolic Health.
Topics: Biomarkers; Citric Acid Cycle; Diabetes Mellitus, Type 2; Fasting; Humans; Lactic Acid; Metabolic Sy | 2020 |
4 trials available for lactic acid and Metabolic Syndrome
| Article | Year |
|---|---|
EFFECT OF MAGNESIUM L-LACTATE SUPPLEMENT ON BLOOD PRESSURE AND CORRECTED QT INTERVAL IN A SAMPLE OF IRAQI WOMEN WITH METABOLIC SYNDROME.
Topics: Blood Pressure; Blood Pressure Monitoring, Ambulatory; Female; Humans; Hypertension; Iraq; Lactic Ac | 2023 |
Interaction Between Lactate and Uric Acid is Associated With a Higher Prevalence of Metabolic Syndrome: A Community-Based Study.
Topics: Adult; C-Reactive Protein; China; Cross-Sectional Studies; Female; Humans; Insulin Resistance; Lacti | 2019 |
Effects of Wearing Compression Stockings on the Physical Performance of T2DM Men with MetS.
Topics: Aged; Cross-Over Studies; Diabetes Mellitus, Type 2; Erythrocyte Deformability; Exercise Test; Hemod | 2016 |
Exercise training increases electron and substrate shuttling proteins in muscle of overweight men and women with the metabolic syndrome.
Topics: Adult; Blood Glucose; Exercise; Female; Gene Expression Regulation; Humans; Lactic Acid; Male; Metab | 2005 |
17 other studies available for lactic acid and Metabolic Syndrome
| Article | Year |
|---|---|
[EXPERIMENTAL JUSTIFICATION OF CORRECTIVE ACTION OF NATIVE AND SELENIUM-MODIFIED MINERAL WATERS ON METABOLIC SYNDROME MODEL].
Topics: Animals; Lactic Acid; Male; Metabolic Syndrome; Mineral Waters; Rats; Selenium; Urea | 2022 |
High-Molecular-Weight Dextran-Type Exopolysaccharide Produced by the Novel
Topics: Animals; Antioxidants; Bees; Blood Glucose; Cholesterol; Dextrans; Lactic Acid; Metabolic Syndrome; | 2022 |
The Relationship of VO
Topics: Aged; Anaerobic Threshold; Blood Glucose; Blood Pressure; Body Mass Index; Cardiorespiratory Fitness | 2020 |
LACTATE CAN BE A MARKER OF METABOLIC SYNDROME IN SEVERE OBESITY?
Topics: Body Mass Index; Case-Control Studies; Gastric Bypass; Humans; Lactic Acid; Metabolic Syndrome; Obes | 2021 |
High fat diet administration leads to the mitochondrial dysfunction and selectively alters the expression of class 1 GLUT protein in mice.
Topics: Adipose Tissue; Animals; Body Weight; Diet, High-Fat; Gene Expression Regulation; Glucose Transporte | 2019 |
Isocaloric Fructose Restriction Reduces Serum d-Lactate Concentration in Children With Obesity and Metabolic Syndrome.
Topics: Adipose Tissue; Adolescent; Black or African American; Carbon-13 Magnetic Resonance Spectroscopy; Ch | 2019 |
Plasma lactate as a marker of metabolic health: Implications of elevated lactate for impairment of aerobic metabolism in the metabolic syndrome.
Topics: Adult; Fasting; Female; Follow-Up Studies; Gastric Bypass; Humans; Lactic Acid; Male; Metabolic Synd | 2019 |
Diversity in the utilization of glucose and lactate in synthetic mammalian myotubes generated by engineered configurations of MyoD and E12 in otherwise non-differentiation growth conditions.
Topics: Animals; Biocompatible Materials; Biological Transport; Calcium; Glucose; Glucose Transporter Type 4 | 2015 |
Isocaloric fructose restriction and metabolic improvement in children with obesity and metabolic syndrome.
Topics: Absorptiometry, Photon; Adiposity; Adolescent; Black or African American; Blood Pressure; Body Weigh | 2016 |
Metabolomic profiling to dissect the role of visceral fat in cardiometabolic health.
Topics: Absorptiometry, Photon; Aged; Amino Acids, Branched-Chain; Blood Glucose; Blood Pressure; Body Mass | 2016 |
MiR-206 is expressed in pancreatic islets and regulates glucokinase activity.
Topics: Animals; Computer Simulation; Diet, High-Fat; Glucokinase; Glucose; Glucose Tolerance Test; Glycogen | 2016 |
Cardiovascular Drift during Training for Fitness in Patients with Metabolic Syndrome.
Topics: Blood Pressure; Body Temperature; Cardiac Output; Dehydration; Energy Metabolism; Heart Rate; High-I | 2017 |
Association of lactate with blood pressure before and after rapid weight loss.
Topics: Adipose Tissue; Adult; Aged; Biomarkers; Blood Pressure; Body Mass Index; Case-Control Studies; Diet | 2008 |
Impact of early fructose intake on metabolic profile and aerobic capacity of rats.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weights and Measures; Dietary Carbohydrates; Disease Mo | 2011 |
Intrauterine growth retardation increases the susceptibility of pigs to high-fat diet-induced mitochondrial dysfunction in skeletal muscle.
Topics: Animals; Blood Glucose; Diet, High-Fat; DNA, Mitochondrial; Eating; Female; Fetal Growth Retardation | 2012 |
Reproducibility and levels of blood lactate transition thresholds in persons with metabolic syndrome.
Topics: Adult; Anaerobic Threshold; Case-Control Studies; Electrocardiography; Electronic Data Processing; E | 2013 |
1H NMR metabonomics approach to the disease continuum of diabetic complications and premature death.
Topics: Acetates; Adult; Albuminuria; Antihypertensive Agents; Apolipoproteins B; Biomarkers; Cholesterol; C | 2008 |